Aurobindo Pharma announced that the company has appointed Sanjeev Dani, former senior executive with Ranbaxy Laboratories, as chief operating officer and head of formulation business. Dani, who quit Ranbaxy in 2014, will lead the front-end operations of emerging markets and Europe. He has replaced Arvind Vasudeva, who was in this role since November 2012.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,256 INR | +0.40% | +5.92% | +15.85% |
05/06 | Hindalco-owned Novelis delays US IPO; shares slide | RE |
27/05 | Aurobindo Pharma Clocks Gains in Fiscal Q4 Consolidated Net Profit | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.85% | 8.78B | |
+43.64% | 754B | |
+39.42% | 630B | |
-6.58% | 352B | |
+19.72% | 331B | |
+8.78% | 298B | |
+11.92% | 217B | |
-2.62% | 216B | |
+0.03% | 163B | |
+6.13% | 164B |
- Stock Market
- Equities
- AUROPHARMA Stock
- News Aurobindo Pharma
- Sanjeev Dani Joins Aurobindo Pharma as COO